BHARAT BIOTECH INTERNATIONAL LIMITED

Experts at Asia Economic Dialogue stressed the need to address vaccine hesitancy and global vaccine inequity, highlighting India's role as a major vaccine manufacturer. They emphasized greater government engagement with manufacturers and community education for vaccination, noting India's rapid vaccine development and regulatory efficiency. The discussion also touched on future pandemic preparedness and the utilization of current vaccine production capacities.

Despite significant global efforts to incentivize antibiotic R&D, coordination gaps, funding shortages, and misaligned incentives hinder innovation. AMR research faces challenges from insufficient funding, high R&D costs, and low market profitability. Investments in AMR could yield substantial economic benefits, but current incentives are insufficient. Academic and small enterprises lead antibiotic research, but lack funds for clinical trials. Push and pull funding models are needed to sustain antibiotic development. Pharmaceutical companies avoid AMR research due to low profitability and regulatory challenges. Urgent action is required to address the growing threat of AMR, with academic research playing a crucial role in developing innovative solutions.

India's biopharma industry advances with biosimilar approvals, biomanufacturing, and precision therapeutics, supported by government initiatives like the BioE3 Policy and PLI Schemes. The sector integrates AI, continuous manufacturing, and biofoundries, positioning India as a global leader in biologics and biosimilars, with a focus on sustainable practices and personalized medicine.

Asia-Pacific leads in vaccine development with 46% of global prophylactic trials and 31% of therapeutic trials, driven by technological innovations, strategic investments, and regional collaborations. The industry shifts from prophylactic to therapeutic applications, with mRNA and viral vector platforms, genomics, AI, and therapeutic innovations in oncology shaping the future. Challenges include vaccine equity, regulatory complexities, and public hesitancy, but strategic investments and collaborations are reshaping the sector.

DelveInsight's 'Tetanus Pipeline Insight 2024' report highlights 20+ companies developing 20+ pipeline tetanus drugs, including GC 3111A, KD-370, and TNM 002. Key companies like G C Pharma and KM Biologics are advancing therapies, with promising candidates in various clinical phases. The report also notes a study suggesting tetanus vaccination may reduce Parkinson's disease occurrence.

Bharat BioTech plans to conduct COVID-19 vaccine COVAXIN trials on 375 people, aiming for an August 15 launch, despite expert criticism of the timeline. Two other companies, Zydus Pharma and BioNTech, have also announced vaccine candidates. India ranks third globally in COVID-19 cases.

Kerala is positioning itself as a leader in healthcare and biotechnology, with plans for new Centres of Excellence and Life Sciences Parks to drive innovation and entrepreneurship.

ICMR formalizes MoAs with sponsors for phase 1 clinical trials of four promising molecules, including research on multiple myeloma, Zika vaccine, seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukaemia, aiming to establish India as a leader in pharmaceutical agent development.

ICMR signs agreements with industry giants to advance first-in-human phase 1 clinical trials for four promising molecules, aiming to establish India as a leader in pharmaceutical agent development and provide accessible healthcare treatments.